Equity Profile

ARQT

Arcutis Biotherapeutics, Inc.

Health CareBiotechnology$2.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be looking for signs of improvement or continued losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases. With a market cap of $3 billion, it operates in the health care sector, aiming to address unmet needs in dermatology, which is a growing area of interest as skin conditions affect millions of people worldwide.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

In Q1-2026, Arcutis reported an EPS of -$0.09, which was significantly below the estimate of -$0.02, resulting in a negative surprise. Despite this, the stock rose by 3.20% the following day, reflecting some investor optimism.

Management Promises & Guidance

Management committed to advancing their product pipeline.
They indicated plans for increased marketing efforts for their existing products.
They expressed confidence in upcoming clinical trials.

Expectations

Wall Street Expectations

Overall, expectations are mixed, with some investors hopeful for a turnaround in profitability while others remain cautious due to recent losses. The market will be closely watching for any signs of revenue growth or positive updates from the product pipeline.

Bull Case

If Arcutis can show improved EPS and strong revenue growth, it could validate investor confidence and lead to a significant stock price increase. Positive updates on their product pipeline could also boost sentiment.

Bear Case

On the other hand, continued losses and lack of revenue growth could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS will be a critical indicator of the company's profitability and will heavily influence investor sentiment.

What updates will be provided on the product pipeline?

Any new information regarding product development or clinical trials could significantly impact future revenue expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcutis to turn around its financials this quarter, especially given the recent positive surprises in EPS.

Supporting Evidence

The company's recent history shows an 88% EPS beat rate, indicating a strong potential for positive surprises.

Despite the negative EPS last quarter, the stock still gained 3.20%, suggesting underlying investor confidence.

Options pricing suggests a significant move, indicating that investors are bracing for potential volatility.

Key Risk

If the EPS comes in better than -$0.05, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to show progress in profitability and product development.

Bull Confirmed If

An EPS of -$0.05 or better, along with positive updates on the product pipeline, would support a bullish outlook.

Bear Confirmed If

An EPS worse than -$0.10 and no significant updates on the product pipeline would confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.85%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors anticipate volatility.

Options are pricing a much larger move than the historical average, indicating heightened uncertainty.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests a stock increase of around 2.7%, confirming a positive sentiment about their growth prospects.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting cautious optimism or skepticism from investors.

Miss

If the company misses expectations, history suggests a potential drop of about 3.2%, indicating disappointment in the market.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·1 sell

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the product pipeline and any upcoming clinical trial results.
2Management's outlook on revenue growth for the next quarter.
3Any changes to marketing strategies for existing products.
4Insights into cost management and operational efficiency improvements.
5Updates on competitive positioning in the dermatology market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Arcutis Biotherapeutics, Inc. (ARQT) is a biotechnology company focused on developing innovative treatments for skin diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be looking for signs of improvement or continued losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and validate its product pipeline.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ARQT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.67%

Avg Stock Reaction

+2.77%

Last Quarter Recap

Management Promises & Guidance

Management committed to advancing their product pipeline.
They indicated plans for increased marketing efforts for their existing products.
They expressed confidence in upcoming clinical trials.

Expectations

Wall Street Expectations

Bull Case

Bear Case

On the other hand, continued losses and lack of revenue growth could lead to further declines in stock price, as investors may lose faith in the company's ability to execute its strategy.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS will be a critical indicator of the company's profitability and will heavily influence investor sentiment.

What updates will be provided on the product pipeline?

Any new information regarding product development or clinical trials could significantly impact future revenue expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Arcutis to turn around its financials this quarter, especially given the recent positive surprises in EPS.

Supporting Evidence

The company's recent history shows an 88% EPS beat rate, indicating a strong potential for positive surprises.

Despite the negative EPS last quarter, the stock still gained 3.20%, suggesting underlying investor confidence.

Options pricing suggests a significant move, indicating that investors are bracing for potential volatility.

Key Risk

If the EPS comes in better than -$0.05, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to show progress in profitability and product development.

Bull Confirmed If

An EPS of -$0.05 or better, along with positive updates on the product pipeline, would support a bullish outlook.

Bear Confirmed If

An EPS worse than -$0.10 and no significant updates on the product pipeline would confirm a bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±18.36%

Historical Avg

±5.85%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that investors anticipate volatility.

Options are pricing a much larger move than the historical average, indicating heightened uncertainty.

Detail

ATM IV

0.7%

30d HV

62.0%

Calls (13K)P/C Ratio: 0.14Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arcutis beats expectations, history suggests a stock increase of around 2.7%, confirming a positive sentiment about their growth prospects.

In-Line / Cautious

If results are in line with expectations, the stock may react moderately, reflecting cautious optimism or skepticism from investors.

Miss

If the company misses expectations, history suggests a potential drop of about 3.2%, indicating disappointment in the market.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·1 sell

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the product pipeline and any upcoming clinical trial results.
2Management's outlook on revenue growth for the next quarter.
3Any changes to marketing strategies for existing products.
4Insights into cost management and operational efficiency improvements.
5Updates on competitive positioning in the dermatology market.